{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:13:23Z","timestamp":1778836403769,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019402","name":"Puma Biotechnology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP150535"],"award-info":[{"award-number":["RP150535"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["1UM1TR0045906"],"award-info":[{"award-number":["1UM1TR0045906"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015725","name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy","doi-asserted-by":"publisher","award":["UM1 TR0045906"],"award-info":[{"award-number":["UM1 TR0045906"]}],"id":[{"id":"10.13039\/100015725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015725","name":"Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy","doi-asserted-by":"publisher","award":["1UL1 TR003167"],"award-info":[{"award-number":["1UL1 TR003167"]}],"id":[{"id":"10.13039\/100015725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105895","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T20:34:24Z","timestamp":1763066064000},"page":"105895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-1660","authenticated-orcid":false,"given":"S.A.","family":"Piha-Paul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.E.","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-3309","authenticated-orcid":false,"given":"T.A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7983-3264","authenticated-orcid":false,"given":"J.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.B.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.L.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.T.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105895_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105895_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB receptors and signaling pathways in cancer","volume":"21","author":"Hynes","year":"2009","journal-title":"Curr Opin Cell Biol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.105895_bib5","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"issue":"43","key":"10.1016\/j.esmoop.2025.105895_bib6","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1038\/sj.onc.1205847","article-title":"Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells","volume":"21","author":"Timms","year":"2002","journal-title":"Oncogene"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105895_bib7","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105895_bib8","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1078-0432.CCR-08-1978","article-title":"A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors","volume":"15","author":"Wong","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105895_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ardp.200800009","article-title":"The development of HKI-272 and related compounds for the treatment of cancer","volume":"341","author":"Wissner","year":"2008","journal-title":"Arch Pharm (Weinheim)"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105895_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105895_bib12","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","article-title":"U.S. Food and Drug Administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer","volume":"24","author":"Singh","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"27","key":"10.1016\/j.esmoop.2025.105895_bib13","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105895_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105895_bib15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol"},{"issue":"7015","key":"10.1016\/j.esmoop.2025.105895_bib16","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 cell-cycle control and cancer","volume":"432","author":"Massague","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2025.105895_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891580","article-title":"CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review","volume":"12","author":"Rampioni Vinciguerra","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105895_bib18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1078-0432.CCR-19-2580","article-title":"FDA approval summary: palbociclib for male patients with metastatic breast cancer","volume":"26","author":"Wedam","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105895_bib19","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","article-title":"FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"22","author":"Walker","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105895_bib20","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105895_bib21","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105895_bib22","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.biopha.2018.10.170","article-title":"Palbociclib overcomes afatinib resistance in non-small cell lung cancer","volume":"109","author":"Nie","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"7-8","key":"10.1016\/j.esmoop.2025.105895_bib23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.18632\/genesandcancer.24","article-title":"CDK4\/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models","volume":"5","author":"Witkiewicz","year":"2014","journal-title":"Genes Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105895_bib24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1158\/1078-0432.CCR-20-3017","article-title":"Combining neratinib with CDK4\/6, mTOR, and MEK inhibitors in models of HER2-positive cancer","volume":"27","author":"Zhao","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105895_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/gutjnl-2020-323276","article-title":"Pan-ERBB kinase inhibition augments CDK4\/6 inhibitor efficacy in oesophageal squamous cell carcinoma","volume":"71","author":"Zhou","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/15384047.2018.1507665","article-title":"Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition","volume":"20","author":"Booth","year":"2019","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105895_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105895_bib28","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.drudis.2015.05.013","article-title":"The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform","volume":"20","author":"Johnson","year":"2015","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105895_bib30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpba.2016.11.035","article-title":"LC-MS\/MS assay for the quantitation of the tyrosine kinase Inhibitor neratinib in human plasma","volume":"134","author":"Kiesel","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.esmoop.2025.105895_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jpba.2019.06.034","article-title":"Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma","volume":"174","author":"Janssen","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105895_bib32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/cas.12932","article-title":"Phase I study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients","volume":"107","author":"Tamura","year":"2016","journal-title":"Cancer Sci"},{"issue":"7691","key":"10.1016\/j.esmoop.2025.105895_bib33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105895_bib34","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1007\/s10528-024-10704-w","article-title":"The CDK4\/6 inhibitor palbociclib induces cell senescence of high-grade serous ovarian cancer through acetylation of p53","volume":"62","author":"Ye","year":"2024","journal-title":"Biochem Genet"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2159-8290.CD-19-0966","article-title":"Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2025.105895_bib36","article-title":"Survival outcomes by TP53 mutation status in metastatic breast cancer","volume":"2018","author":"Meric-Bernstam","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2025.105895_bib37","article-title":"Metabolic profiles of neratinib in rat by using ultra-high-performance liquid chromatography coupled with diode array detector and Q-Exactive Orbitrap tandem mass spectrometry","author":"Liu","year":"2018","journal-title":"Biomed Chromatogr"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105895_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10637-022-01314-7","article-title":"The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux","volume":"41","author":"Qi","year":"2023","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105895_bib40","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s10637-015-0266-y","article-title":"P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4\/6 inhibitor palbociclib","volume":"33","author":"de Gooijer","year":"2015","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105895_bib41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cpt.2455","article-title":"Effects of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib: a randomized crossover trial in patients with breast cancer","volume":"111","author":"Molenaar-Kuijsten","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105895_bib42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/pharmaceutics14071317","article-title":"Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer","volume":"14","author":"Courlet","year":"2022","journal-title":"Pharmaceutics"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105895_bib43","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1158\/1078-0432.CCR-16-0592","article-title":"Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials","volume":"22","author":"Yuan","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105895_bib44","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-22-3334","article-title":"National Cancer Institute combination therapy platform trial with molecular analysis for therapy choice (ComboMATCH)","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:49:37Z","timestamp":1778834977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017648"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105895","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105895"}}